Organogenesis has the skinny on replacement tissue. Its flagship product, Apligraf, is a human skin substitute approved to treat diabetic foot ulcers and venous leg ulcers caused by poor circulation. It has delivered more than 500,000 units of Apligraf for patient treatment. Rejection-resistant Apligraf is bio-engineered using living skin cells and has been used to treat chronic open wounds. Founded in 1985, the company is developing a next-generation of the material using all human components via its VCT technology. It also offers a line of biomaterials used in a range of surgical procedures to seal or reconstruct soft tissue and develops regenerative technologies in the area of cosmetic skin rejuvenation.
Biotechnology- wound care and surgical and sports medicine